Login to Your Account

HSV-2 Trials Are a Priority

Genocea Biosciences Closes $35M Series B Financing

By Tom Wall

Monday, January 3, 2011
Genocea Biosciences Inc. has closed a $35 million Series B round of venture financing that the company expects will take it deep into clinical development of its lead program, a therapeutic vaccine for herpes simplex virus type 2 (HSV-2) infections, and bring candidates for chlamydia, pneumonia, malaria and herpes prophylaxis in its pipeline up to the clinical stage.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription